STAAR Surgical Company comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs. New clinical data during the scientific session continues to support EVO ICL patient advantages and provide insights to guide successful implementation in practice. On April 6, 2024, a study showcasing ?Outcomes of 229 Consecutive EVO Implantable Collamer Lenses in a US Based Single Center Study?

will be presented by Taj Nasser, MD, and co-authors. This is the US commercial use outcomes paper to-date following FDA approval of EVO/EVO+. Also of note is a new diagnostics comparison study by J. Morgan Micheletti, MD, ABO, FACS, which demonstrates a large-scale analysis of measurement variables between eight different readily available diagnostic devices used in the evaluation of refractive surgery patients.